STOCK TITAN

Kala Bio (KALA) director reports no beneficial ownership on Form 3

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

KALA BIO, Inc. director Chaim D. Berger filed an initial insider ownership report on Form 3. The filing states that, as of the event date of 01/30/2026, he beneficially owns no securities of KALA BIO. The form was signed and submitted by attorney-in-fact Avraham Minkowitz under a power of attorney attached as Exhibit 24.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Berger Chaim D.

(Last) (First) (Middle)
1167 MASSACHUSETTS AVENUE

(Street)
ARLINGTON MA 02476

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
01/30/2026
3. Issuer Name and Ticker or Trading Symbol
KALA BIO, Inc. [ KALA ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
The Power of Attorney, executed by the Reporting Person, authorizing Avraham Minkowitz to sign and file this Form 3 on the Reporting Person's behalf is attached hereto as Exhibit 24.
No securities are beneficially owned.
/s/ Avraham Minkowitz, Attorney-in-Fact 02/09/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the KALA BIO (KALA) Form 3 filing by Chaim D. Berger report?

The Form 3 shows that director Chaim D. Berger reported no beneficial ownership of KALA BIO, Inc. securities as of 01/30/2026. This initial insider filing establishes his starting ownership position as zero under Section 16 reporting rules.

What is the event date disclosed in the KALA BIO (KALA) Form 3?

The event date in the Form 3 is 01/30/2026, which is when the reporting requirement was triggered. This date anchors when director Chaim D. Berger’s beneficial ownership status, reported as zero securities, is measured.

What role does Chaim D. Berger have at KALA BIO (KALA) according to the Form 3?

The Form 3 identifies Chaim D. Berger as a director of KALA BIO, Inc. and not a 10% owner or officer. As a director, he must report his beneficial ownership, which this filing states is currently zero securities.

Who signed the KALA BIO (KALA) Form 3 and under what authority?

The Form 3 was signed by Avraham Minkowitz as attorney-in-fact for Chaim D. Berger. A power of attorney authorizing Minkowitz to sign and file on Berger’s behalf is referenced in the remarks and attached as Exhibit 24.

Does the KALA BIO (KALA) Form 3 indicate any securities beneficially owned by the director?

No, the filing explicitly states that no securities are beneficially owned. This means that, as of the 01/30/2026 event date, director Chaim D. Berger reported zero beneficial ownership of KALA BIO, Inc. securities under Section 16 rules.
Kala Pharmaceuticals Inc

NASDAQ:KALA

KALA Rankings

KALA Latest News

KALA Latest SEC Filings

KALA Stock Data

11.56M
8.10M
1.75%
51.86%
5.98%
Biotechnology
Pharmaceutical Preparations
Link
United States
ARLINGTON